Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -15.15% is 36% above its 5-year average of -23.50%, near the high end of its 5-year range (-52.60%–-0.12%).
42.53% above its 12-month average of -26.36%.
Reported quarterly return on assets; no daily interpolation. Q3 FY2026 (2026-06-30): -9.20%.
RETURN ON ASSETS (ROA)
-15.15%
RETURN ON ASSETS (ROA) AVG TTM
-26.36%
RETURN ON ASSETS (ROA) AVG 3Y
-26.24%
RETURN ON ASSETS (ROA) AVG 5Y
-23.50%
RETURN ON ASSETS (ROA) AVG 10Y
-30.61%
RETURN ON ASSETS (ROA) AVG 15Y
-34.57%
RETURN ON ASSETS (ROA) AVG 20Y
-43.44%
CURRENT VS TTM AVG
+42.53%
CURRENT VS 3Y AVG
+42.27%
CURRENT VS 5Y AVG
+35.52%
CURRENT VS 10Y AVG
+50.50%
CURRENT VS 15Y AVG
+56.18%
CURRENT VS 20Y AVG
+65.12%
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+53.05%
vs the sector median at left
Arrowhead Pharmaceuticals, Inc.
Market Cap
$8.67B
Return on Assets (ROA)
-15.15%
TTM Avg
-26.36%
3Y Avg
-26.24%
5Y Avg
-23.50%
Market Cap
$8.72B
Return on Assets (ROA)
-18.21%
TTM Avg
-20.38%
3Y Avg
-22.99%
5Y Avg
-19.64%
Market Cap
$8.92B
Return on Assets (ROA)
9.36%
TTM Avg
8.76%
3Y Avg
-13.98%
5Y Avg
-18.74%
Market Cap
$8.93B
Return on Assets (ROA)
-1.18%
TTM Avg
0.91%
3Y Avg
5.02%
5Y Avg
5.47%
Market Cap
$8.38B
Return on Assets (ROA)
4.91%
TTM Avg
-3.24%
3Y Avg
-6.85%
5Y Avg
-10.42%
Market Cap
$8.97B
Return on Assets (ROA)
-25.17%
TTM Avg
-38.54%
3Y Avg
-43.55%
5Y Avg
-63.00%
Market Cap
$9.21B
Return on Assets (ROA)
-1.18%
TTM Avg
0.91%
3Y Avg
5.02%
5Y Avg
5.47%
Market Cap
$9.33B
Return on Assets (ROA)
11.86%
TTM Avg
10.65%
3Y Avg
7.37%
5Y Avg
5.11%
Market Cap
$7.99B
Return on Assets (ROA)
26.93%
TTM Avg
23.05%
3Y Avg
-16.42%
5Y Avg
-33.67%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals, Inc. (ARWR) | $8.67B | -15.15% | -26.36% | -26.24% | -23.50% |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.72B | -18.21% | -20.38% | -22.99% | -19.64% |
| Protagonist Therapeutics, Inc. (PTGX)vs › | $8.92B | 9.36% | 8.76% | -13.98% | -18.74% |
| Bruker Corporation (BRKRP)vs › | $8.93B | -1.18% | 0.91% | 5.02% | 5.47% |
| Oscar Health, Inc. (OSCR)vs › | $8.38B | 4.91% | -3.24% | -6.85% | -10.42% |
| Axsome Therapeutics, Inc. (AXSM)vs › | $8.97B | -25.17% | -38.54% | -43.55% | -63.00% |
| Bruker Corporation (BRKR)vs › | $9.21B | -1.18% | 0.91% | 5.02% | 5.47% |
| Insulet Corp. (PODD)vs › | $9.33B | 11.86% | 10.65% | 7.37% | 5.11% |
| TG Therapeutics, Inc. (TGTX)vs › | $7.99B | 26.93% | 23.05% | -16.42% | -33.67% |
| Praxis Precision Medicines, Inc. (PRAX)vs › | $7.81B | -24.40% | -35.09% | -99.06% | -78.95% |
ROA
-15.2%
ROE
-68.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-09-30 | -0.12% |
| 2024-09-30 | -52.60% |
| 2023-09-30 | -26.81% |
| 2022-09-30 | -25.44% |
| 2021-09-30 | -19.83% |
| 2020-09-30 | -16.18% |
| 2019-09-30 | 19.43% |
| 2018-09-30 | -48.79% |
| 2017-09-30 | -33.05% |
| 2016-09-30 | -63.76% |
| 2015-09-30 | -69.51% |
| 2014-09-30 | -32.07% |
| 2013-09-30 | -83.43% |
| 2012-09-30 | -127.82% |
| 2011-09-30 | -19.69% |
| 2010-09-30 | -46.74% |
| 2009-09-30 | -250.69% |
| 2008-09-30 | -156.99% |
| 2007-09-30 | -100.26% |
| 2006-09-30 | -55.02% |
| 2005-09-30 | -23.60% |
| 2004-09-30 | -21.22% |
| 2003-09-30 | -6.28% |
| 2002-09-30 | -387.36% |
| 2001-09-30 | -401.30% |
| 2000-09-30 | -211.14% |
| 1999-09-30 | 720.60% |
| 1998-09-30 | -194.65% |
| 1997-09-30 | -793.59% |
